BRCA 1/BRCA 2 PATHOGENIC/LIKELY PATHOGENIC VARIANT PATIENTS WITH BREAST, OVARIAN, AND OTHER CANCERS
Osman K.1,*, Ahmet K.2, Hilmi T.3, İlker N.O.4, Ercan Ö.5, Devrim Ç.5, Murat S.1, Emre Ç.6, İlhan H.6, Mustafa G.7, Yüksel Ü.7, Bahiddin Y.8, Cihan E.9, Mehmet Ali N. Ş.9, Emrah E.10, Umut D.10, Zeynep O.11, Mehmet Ali K.12, Ali G.2, İvo G.2, Erkan Ö.2, Muhammet B. H.2, Bülent E.2, Selma D.12, Sernaz U.2, Mahmut G.4, Hakan G.12, İrfan Ç.2
*Corresponding Author: Assoc. Prof. Osman Köstek, MD, Marmara University, School of Medicine, Department of Medical Oncology Address: Marmara University, Basıbuyuk Campus, Maltepe, Istanbul, Turkey. Email: osmankostek@hotmail.com, Telephone: +90 554 585 73 90
page: 5

REFERENCES

1. A.K. Byrum, A. Vindigni, N. Mosammaparast, Defining and Modulating ‘BRCAness’, Trends Cell Biol. 2019; 29(9): 740-751. 2. M.J. Khoury, W.G. Feero, D.A. Chambers, L.C. Brody, N. Aziz, R.C. Green, A. Janssens, M.F. Murray, L.L. Rodriguez, J.L. Rutter, S.D. Schully, D.M. Winn, G.A. Mensah, A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health, PLoS Med. 2018; 15(8): e1002631. 3. J.J. Grzymski, G. Elhanan, J.A. Morales Rosado, E. Smith, K.A. Schlauch, R. Read, C. Rowan, N. Slotnick, S. Dabe, W.J. Metcalf, B. Lipp, H. Reed, L. Sharma, E. Levin, J. Kao, M. Rashkin, J. Bowes, K. Dunaway, A. Slonim, N. Washington, M. Ferber, A. Bolze, J.T. Lu, Population genetic screening efficiently identifies carriers of autosomal dominant diseases, Nat Med. 2020; 26(8): 1235-1239. 4. K.J. Karczewski, L.C. Francioli, G. Tiao, B.B. Cummings, J. Alföldi, Q. Wang, R.L. Collins, K.M. Laricchia, A. Ganna, D.P. Birnbaum, L.D. Gauthier, H. Brand, M. Solomonson, N.A. Watts, D. Rhodes, M. Singer-Berk, E.M. England, E.G. Seaby, J.A. Kosmicki, R.K. Walters, K. Tashman, Y. Farjoun, E. Banks, T. Poterba, A. Wang, C. Seed, N. Whiffin, J.X. Chong, K.E. Samocha, E. Pierce-Hoffman, Z. Zappala, A.H. O’Donnell-Luria, E.V. Minikel, B. Weisburd, M. Lek, J.S. Ware, C. Vittal, I.M. Armean, L. Bergelson, K. Cibulskis, K.M. Connolly, M. Covarrubias, S. Donnelly, S. Ferriera, S. Gabriel, J. Gentry, N. Gupta, T. Jeandet, D. Kaplan, C. Llanwarne, R. Munshi, S. Novod, N. Petrillo, D. Roazen, V. Ruano-Rubio, A. Saltzman, M. Schleicher, J. Soto, K. Tibbetts, C. Tolonen, G. Wade, M.E. Talkowski, B.M. Neale, M.J. Daly, D.G. MacArthur, The mutational constraint spectrum quantified from variation in 141,456 humans, Nature. 2020; 581(7809): 434-443. 5. S.T. Sherry, M.H. Ward, M. Kholodov, J. Baker, L. Phan, E.M. Smigielski, K. Sirotkin, dbSNP: the NCBI database of genetic variation, Nucleic Acids Res. 2001; 29(1): 308-11. 6. M.J. Landrum, S. Chitipiralla, G.R. Brown, C. Chen, B. Gu, J. Hart, D. Hoffman, W. Jang, K. Kaur, C. Liu, V. Lyoshin, Z. Maddipatla, R. Maiti, J. Mitchell, N. O’Leary, G.R. Riley, W. Shi, G. Zhou, V. Schneider, D. Maglott, J.B. Holmes, B.L. Kattman, ClinVar: improvements to accessing data, Nucleic Acids Res. 2020; 48(D1): D835-d844 7. P.D. Stenson, M. Mort, E.V. Ball, M. Chapman, K. Evans, L. Azevedo, M. Hayden, S. Heywood, D.S. Millar, A.D. Phillips, D.N. Cooper, The Human Gene Mutation Database (HGMD(®)): optimizing its use in a clinical diagnostic or research setting, Hum Genet. 2020; 139(10): 1197-1207. 8. S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster, W.W. Grody, M. Hegde, E. Lyon, E. Spector, K. Voelkerding, H.L. Rehm, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med. 2015; 17(5): 405-24. 9. J. O’Shaughnessy, C. Brezden-Masley, M. Cazzaniga, T. Dalvi, G. Walker, J. Bennett, S. Ohsumi, Prevalence of germline BRCA mutations in HER2- negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study, Breast Cancer Res. 2020; 22(1): 114. 10. K.B. Kuchenbaecker, J.L. Hopper, D.R. Barnes, K.A. Phillips, T.M. Mooij, M.J. Roos-Blom, S. Jervis, F.E. van Leeuwen, R.L. Milne, N. Andrieu, D.E. Goldgar, M.B. Terry, M.A. Rookus, D.F. Easton, A.C. Antoniou, L. McGuffog, D.G. Evans, D. Barrowdale, D. Frost, J. Adlard, K.R. Ong, L. Izatt, M. Tischkowitz, R. Eeles, R. Davidson, S. Hodgson, S. Ellis, C. Nogues, C. Lasset, D. Stoppa-Lyonnet, J.P. Fricker, L. Faivre, P. Berthet, M.J. Hooning, L.E. van der Kolk, C.M. Kets, M.A. Adank, E.M. John, W.K. Chung, I.L. Andrulis, M. Southey, M.B. Daly, S.S. Buys, A. Osorio, C. Engel, K. Kast, R.K. Schmutzler, T. Caldes, A. Jakubowska, J. Simard, M.L. Friedlander, S.A. McLachlan, E. Machackova, L. Foretova, Y.Y. Tan, C.F. Singer, E. Olah, A.M. Gerdes, B. Arver, H. Olsson, Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, Jama. 2017; 317(23): 2402-2416. 11. M. Okano, T. Nomizu, K. Tachibana, M. Nagatsuka, M. Matsuzaki, N. Katagata, T. Ohtake, S. Yokoyama, M. Arai, S. Nakamura, The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database, J Hum Genet. 2021; 66(3): 307-314. 12. S. Chen, G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance, J Clin Oncol 2007; 25(11): 1329-33. 13. V. Sunar, V. Korkmaz, V. Topcu, B. Cavdarli, Z. Arik, B. Ozdal, Y.E. Ustun, Frequency of germline BRCA 1/BRCA 2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer, Asia Pac J Clin Oncol. 2021. 14. A.L. Siu, Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med. 2016; 164(4): 279-96. 15. D.P. Atchley, C.T. Albarracin, A. Lopez, V. Valero, C.I. Amos, A.M. Gonzalez-Angulo, G.N. Hortobagyi, B.K. Arun, Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer, J Clin Oncol. 2008; 26(26): 4282-8. 16. E. Lee, R. McKean-Cowdin, H. Ma, D.V. Spicer, D. Van Den Berg, L. Bernstein, G. Ursin, Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women, J Clin Oncol. 2011; 29(33): 4373-80. 17. E.V. Høgdall, M. Ringsholt, C.K. Høgdall, I.J. Christensen, J.S. Johansen, S.K. Kjaer, J. Blaakaer, L. Ostenfeld- Møller, P.A. Price, L.H. Christensen, YKL-40 tissue expression and plasma levels in patients with ovarian cancer, BMC Cancer 9 2009; 8. 18. C. Hu, E.C. Polley, S. Yadav, J. Lilyquist, H. Shimelis, J. Na, S.N. Hart, D.E. Goldgar, S. Shah, T. Pesaran, J.S. Dolinsky, H. LaDuca, F.J. Couch, The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort, J Natl Cancer Inst. 2020; 112(12): 1231-1241. 19. E. Fountzilas , I. Konstantopoulou , A. Vagena , P. Apostolou , C. Papadimitriou , C. Christodoulou, D. Tryfonopoulos , K. Manousou, A. Delimitsou , M. Papamentzelopoulou, G. Fountzilas , D. Yannoukakos , F. Fostira, Pathology of BRCA1- and BRCA2- associated Breast Cancers: Known and Less Known Connections. Clin Breast Cancer.2020; 20(2): 152-59. 20. Y. Laitman, T.M Friebel, D. Yannoukakos, F. Fostira, I. Konstantopoulou, G. Figlioli, B. Bonanni, S. Manoukian, M. Zuradelli, C. Tondini, B. Pasini, P. Peterlongo , D. Plaseska-Karanfilska, M. Jakimovska, K. Majidzadeh , S. Zarinfam , M.A Loizidou , A. Hadjisavvas, K. Michailidou , K. Kyriacou, D. M Behar, R. B Molho, P. Ganz, P. James , M.T Parsons, A. Sallam , O.I Olopade , A. Seth, G. Chenevix-Trench , G. Leslie, L. McGuffog, M.J Marafie , A. Megarbane, F. Al-Mulla, T.R Rebbeck , E. Friedman, The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Hum Mutat. 2019; 40(11): 1-23. 21]T. Mitamura, M. Sekine, M. Arai, Y. Shibata, M. Kato, S. Yokoyama, H. Yamashita, H. Watari, I. Yabe, H. Nomura, T. Enomoto, S. Nakamura, The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study, World J Surg Oncol. 2021; 19(1): 36. 22. M. Arts-de Jong, G.H. de Bock, C.J. van Asperen, M.J. Mourits, J.A. de Hullu, C.M. Kets, Germline BRCA 1/BRCA 2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review, Eur J Cancer. 2016; 61: 137-45. 23. S.R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J.G. Klijn, H. Meijers-Heijboer, P. Radice, S. Pilotti, H. Nevanlinna, R. Butzow, H. Sobol, J. Jacquemier, D.S. Lyonet, S.L. Neuhausen, B. Weber, T. Wagner, R. Winqvist, Y.J. Bignon, F. Monti, F. Schmitt, G. Lenoir, S. Seitz, U. Hamman, P. Pharoah, G. Lane, B. Ponder, D.T. Bishop, D.F. Easton, Pathology of ovarian cancers in BRCA1 and BRCA2 carriers, Clin Cancer Res. 2004; 10(7): 2473-81. 24. B.M. Norquist, M.I. Harrell, M.F. Brady, T. Walsh, M.K. Lee, S. Gulsuner, S.S. Bernards, S. Casadei, Q. Yi, R.A. Burger, J.K. Chan, S.A. Davidson, R.S. Mannel, P.A. DiSilvestro, H.A. Lankes, N.C. Ramirez, M.C. King, E.M. Swisher, M.J. Birrer, Inherited Mutations in Women With Ovarian Carcinoma, JAMA Oncol. 2016; 2(4): 482-90. 25. K.L. Bolton, G. Chenevix-Trench, C. Goh, S. Sadetzki, S.J. Ramus, B.Y. Karlan, D. Lambrechts, E. Despierre, D. Barrowdale, L. McGuffog, S. Healey, D.F. Easton, O. Sinilnikova, J. Benítez, M.J. García, S. Neuhausen, M.H. Gail, P. Hartge, S. Peock, D. Frost, D.G. Evans, R. Eeles, A.K. Godwin, M.B. Daly, A. Kwong, E.S. Ma, C. Lázaro, I. Blanco, M. Montagna, E. D’Andrea, M.O. Nicoletto, S.E. Johnatty, S.K. Kjær, A. Jensen, E. Høgdall, E.L. Goode, B.L. Fridley, J.T. Loud, M.H. Greene, P.L. Mai, A. Chetrit, F. Lubin, G. Hirsh-Yechezkel, G. Glendon, I.L. Andrulis, A.E. Toland, L. Senter, M.E. Gore, C. Gourley, C.O. Michie, H. Song, J. Tyrer, A.S. Whittemore, V. McGuire, W. Sieh, U. Kristoffersson, H. Olsson, Å. Borg, D.A. Levine, L. Steele, M.S. Beattie, S. Chan, R.L. Nussbaum, K.B. Moysich, J. Gross, I. Cass, C. Walsh, A.J. Li, R. Leuchter, O. Gordon, M. Garcia- Closas, S.A. Gayther, S.J. Chanock, A.C. Antoniou, P.D. Pharoah, Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer, Jama. 2012; 307(4): 382-90. 26. A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, S. Sadetzki, Effect of BRCA 1/ BRCA 2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer, J Clin Oncol. 2008; 26(1): 20-5. 27. D.S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, S. Shanley, A. Ardern-Jones, A. Norman, S.B. Kaye, M.E. Gore, “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations, J Clin Oncol. 2008; 26(34): 5530-6. 28. D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich, A.K. Sood, W. Zhang, Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer, Jama. 2011; 306(14): 1557-65. 29. C.C. Pritchard, J. Mateo, M.F. Walsh, N. De Sarkar, W. Abida, H. Beltran, A. Garofalo, R. Gulati, S. Carreira, R. Eeles, O. Elemento, M.A. Rubin, D. Robinson, R. Lonigro, M. Hussain, A. Chinnaiyan, J. Vinson, J. Filipenko, L. Garraway, M.E. Taplin, S. AlDubayan, G.C. Han, M. Beightol, C. Morrissey, B. Nghiem, H.H. Cheng, B. Montgomery, T. Walsh, S. Casadei, M. Berger, L. Zhang, A. Zehir, J. Vijai, H.I. Scher, C. Sawyers, N. Schultz, P.W. Kantoff, D. Solit, M. Robson, E.M. Van Allen, K. Offit, J. de Bono, P.S. Nelson, Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer, N Engl J Med. 2016; 375(5): 443-53. 30. E. Castro, C. Goh, D. Olmos, E. Saunders, D. Leongamornlert, M. Tymrakiewicz, N. Mahmud, T. Dadaev, K. Govindasami, M. Guy, E. Sawyer, R. Wilkinson, A. Ardern-Jones, S. Ellis, D. Frost, S. Peock, D.G. Evans, M. Tischkowitz, T. Cole, R. Davidson, D. Eccles, C. Brewer, F. Douglas, M.E. Porteous, A. Donaldson, H. Dorkins, L. Izatt, J. Cook, S. Hodgson, M.J. Kennedy, L.E. Side, J. Eason, A. Murray, A.C. Antoniou, D.F. Easton, Z. Kote-Jarai, R. Eeles, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol. 2013; 31(14): 1748-57. 31. R. Na, S.L. Zheng, M. Han, H. Yu, D. Jiang, S. Shah, C.M. Ewing, L. Zhang, K. Novakovic, J. Petkewicz, K. Gulukota, D.L. Helseth, Jr., M. Quinn, E. Humphries, K.E. Wiley, S.D. Isaacs, Y. Wu, X. Liu, N. Zhang, C.H. Wang, J. Khandekar, P.J. Hulick, D.H. Shevrin, K.A. Cooney, Z. Shen, A.W. Partin, H.B. Carter, M.A. Carducci, M.A. Eisenberger, S.R. Denmeade, M. McGuire, P.C. Walsh, B.T. Helfand, C.B. Brendler, Q. Ding, J. Xu, W.B. Isaacs, Germline Mutations in ATM and BRCA 1/BRCA 2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death, Eur Urol. 2017; 71(5): 740-747. 32. E. Castro, N. Romero-Laorden, A. Del Pozo, R. Lozano, A. Medina, J. Puente, J.M. Piulats, D. Lorente, M.I. Saez, R. Morales-Barrera, E. Gonzalez-Billalabeitia, Y. Cendón, I. García-Carbonero, P. Borrega, M.J. Mendez Vidal, A. Montesa, P. Nombela, E. Fernández-Parra, A. Gonzalez Del Alba, J.C. Villa- Guzmán, K. Ibáñez, A. Rodriguez-Vida, L. Magraner- Pardo, B. Perez-Valderrama, E. Vallespín, E. Gallardo, S. Vazquez, C.C. Pritchard, P. Lapunzina, D. Olmos, PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration- Resistant Prostate Cancer, J Clin Oncol. 2019; 37(6): 490-503. 33. J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop, R. Perez-Lopez, D. Nava Rodrigues, D. Robinson, A. Omlin, N. Tunariu, G. Boysen, N. Porta, P. Flohr, A. Gillman, I. Figueiredo, C. Paulding, G. Seed, S. Jain, C. Ralph, A. Protheroe, S. Hussain, R. Jones, T. Elliott, U. McGovern, D. Bianchini, J. Goodall, Z. Zafeiriou, C.T. Williamson, R. Ferraldeschi, R. Riisnaes, B. Ebbs, G. Fowler, D. Roda, W. Yuan, Y.M. Wu, X. Cao, R. Brough, H. Pemberton, R. A’Hern, A. Swain, L.P. Kunju, R. Eeles, G. Attard, C.J. Lord, A. Ashworth, M.A. Rubin, K.E. Knudsen, F.Y. Feng, A.M. Chinnaiyan, E. Hall, J.S. de Bono, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer, N Engl J Med. 2015; 373(18): 1697-708. 34. J. Mateo, N. Porta, D. Bianchini, U. McGovern, T. Elliott, R. Jones, I. Syndikus, C. Ralph, S. Jain, M. Varughese, O. Parikh, S. Crabb, A. Robinson, D. McLaren, A. Birtle, J. Tanguay, S. Miranda, I. Figueiredo, G. Seed, C. Bertan, P. Flohr, B. Ebbs, P. Rescigno, G. Fowler, A. Ferreira, R. Riisnaes, R. Pereira, A. Curcean, R. Chandler, M. Clarke, B. Gurel, M. Crespo, D. Nava Rodrigues, S. Sandhu, A. Espinasse, P. Chatfield, N. Tunariu, W. Yuan, E. Hall, S. Carreira, J.S. de Bono, Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial, Lancet Oncol. 2020; 21(1): 162-174. 35. J. de Bono, J. Mateo, K. Fizazi, F. Saad, N. Shore, S. Sandhu, K.N. Chi, O. Sartor, N. Agarwal, D. Olmos, A. Thiery-Vuillemin, P. Twardowski, N. Mehra, C. Goessl, J. Kang, J. Burgents, W. Wu, A. Kohlmann, C.A. Adelman, M. Hussain, Olaparib for Metastatic Castration-Resistant Prostate Cancer, N Engl J Med. 2020; 382(22): 2091-2102. 36. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, I.F. Tannock, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol. 2008; 26(2): 242-5. 37. K.M. Murphy, K.A. Brune, C. Griffin, J.E. Sollenberger, G.M. Petersen, R. Bansal, R.H. Hruban, S.E. Kern, Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%, Cancer Res. 2002; 62(13): 3789-93. 38. Cancer risks in BRCA2 mutation carriers, J Natl Cancer Inst. 1999; 91(15): 1310-6.



Number 26
Number 26 VOL. 26(2), 2023 All in one
Number 26
VOL. 26(2), 2023
Number 26
VOL. 26, 2023 Supplement
Number 26
VOL. 26(1), 2023
Number 25
VOL. 25(2), 2022
Number 25
VOL. 25 (1), 2022
Number 24
VOL. 24(2), 2021
Number 24
VOL. 24(1), 2021
Number 23
VOL. 23(2), 2020
Number 22
VOL. 22(2), 2019
Number 22
VOL. 22(1), 2019
Number 22
VOL. 22, 2019 Supplement
Number 21
VOL. 21(2), 2018
Number 21
VOL. 21 (1), 2018
Number 21
VOL. 21, 2018 Supplement
Number 20
VOL. 20 (2), 2017
Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006